Market Research
High Content Screening Market Worth USD 909.0 Million : Application of HCS in Personalized Medicine
The HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments. The software segment is expected to register the highest growth during the forecast period.
[166 Pages Report] MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (OTC:CAGR) of 10.3% during the forecast period
The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R&D, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.
Market Dynamics
- Need for Cost Containment in Pharmaceutical R&D
- Government Funding and Venture Capital Investments Across Developed Markets
- Advancements in Informatics Solutions and Imaging Instruments
Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391
Need for cost containment in pharmaceutical R&D
According to the California Biomedical Research Association (CBRA), it takes an average of 12 years for a drug to travel from the research lab to the patient, including 1–6 years for toxicology studies alone. In addition, only five in 5,000, or 10%, of the drugs that begin preclinical testing ever make it to human testing. Out of these five, only one is approved for human usage.
HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies. As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies. Moreover, budgetary restrictions among academic institutes restrict the purchase of these instruments.
The geographical regions mapped in the report are:
North America is the largest market for high-content screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. High R&D expenditure, the presence of major pharmaceutical market players, and increasing government support are some of the factors contributing to the large share of North America in the market.
Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=42710391
Some key players mentioned in the research report are:
GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.)
